Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study
- Author(s)
- Magaton, IM; Blondeaux, E; Hamy, AS; Linn, S; Bernstein-Molho, R; Peccatori, FA; Ferrari, A; Carrasco, E; Paluch-Shimon, S; Agostinetto, E; Venturelli, M; Luis, IMV; Rodriguez-Wallberg, KA; Kim, HJ; Sorouri, K; Renaud, T; Moore, HCF; Cui, W; Bajpa, J; Rousset-Jablonski, C; De Marchis, L; Yerushalmi, R; Wong, SM; Han, S; Phillips, KA; Pogoda, K; Puglisi, F; Chirco, A; Duhoux, FP; Meattini, I; Villarreal-Garza, C; Vernieri, C; Bruzzone, M; Demeestere, I; Azim, HA, Jr; Partridge, AH; Lambertini, M;
- Journal Title
- European Journal of Cancer
- Publication Type
- Research article
- Abstract
- INTRODUCTION: Very limited data exist on assisted reproductive technology (ART) use in BRCA1/2 carriers conceiving after breast cancer. This study aimed to investigate the safety of ART to achieve a pregnancy after breast cancer in BRCA1/2 carriers. METHODS: This is an international, hospital-based, retrospective cohort study including BRCA1/2 carriers with a pregnancy after prior breast cancer diagnosis at ≤ 40 years of age between 2000 and 2020. Outcomes were compared between young BRCA1/2 carriers who conceived using ART and those who conceived spontaneously. RESULTS: Among 543 BRCA1/2 carriers with a pregnancy after breast cancer, 436 conceived spontaneously and 107 using ART. Of 107 pregnancies achieved with ART, 45 (42.1 %) were obtained using oocytes/embryo cryopreserved at diagnosis, 33 (30.8 %) after controlled ovarian stimulation for in-vitro-fertilization/intracytoplasmic sperm injection or ovulation induction for intrauterine insemination or planned intercourse after anticancer treatments, 21 (19.6 %) after oocyte donation, while for 8 (7.5 %) patients type of ART was missing. Compared to patients in the no-ART group, those in the ART group were older at the time of conception, had more frequently hormone receptor-positive breast cancer and a longer median time from cancer diagnosis to conception. At a median follow-up of 5.2 years after conception, no apparent detrimental effect of ART on disease-free survival was observed (adjusted HR=0.72, 95 % CI 0.39-1.34). CONCLUSION: In young BRCA1/2 carriers with a pregnancy after breast cancer, ART use did not appear to be associated with increased risk of DFS events.
- Publisher
- Elsevier
- Keywords
- Humans; Female; *Breast Neoplasms/genetics/therapy; Pregnancy; Adult; *Reproductive Techniques, Assisted/adverse effects; Retrospective Studies; *BRCA2 Protein/genetics; *BRCA1 Protein/genetics; Heterozygote; Assisted reproductive technology (ART); Breast cancer; Germline BRCA1/2 pathogenic variants; Oncofertility
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.ejca.2025.115434
- Open Access at Publisher's Site
https://doi.org/10.1016/j.ejca.2025.115434- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-06-02 07:40:49
Last Modified: 2025-06-02 07:41:12